ClinicalTrials.gg
CompletedNCT01370356Updated Sep 1, 2014Results posted

A Study To Evaluate The Efficacy And Safety Of Varenicline Compared To Placebo For Smoking Cessation Through Reduction

A Phase 4 interventional study of Varenicline Tartrate and Placebo in Smoking Cessation, sponsored by Pfizer. Completed at 65 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-01.

Sponsored by Pfizer · Phase 4, Interventional, and Health services research

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,510
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies testing varenicline in Smoking Cessation — 5 open to participants now, 7 under way, 2 of them phase 3. Varenicline · Smoking Cessation.

Enrollment
4th of 110
1,510 · median 209
Started
2011
with 10 others
Phase 4
47 of 110
3 open now
Registered
56th of 110
by date
Lead sponsor
26 of 110
Pfizer

Among the 110 studies testing varenicline in Smoking Cessation, this one is the 4th largest by enrollment, is one of 11 that started in 2011, is one of 47 in phase 4, and was the 56th registered.

Smoking Cessation

1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

5 of the 110 studies testing varenicline in Smoking Cessation are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About varenicline

Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing varenicline in Smoking Cessation, or all of them as a file.
02

Study summary

This study will determine whether varenicline is safe and helps people to quit smoking through reduction when they are not willing/able to make an abrupt quit attempt.

03

Conditions studied

  • Smoking Cessation

Keywords

  • smoking reduction
  • smoking cessation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female cigarette smokers over the age of 18 years who are not willing/able to quit smoking within the next month but who are willing to attempt to reduce their smoking to work toward a quit attempt within the next 3 months.
  • Subjects must have smoked an average of at least 10 cigarettes per day during the past year and during the month prior to the screening visit, with no continuous period of abstinence greater than 3 months in the past year and who have an exhaled carbon monoxide (CO) >10 ppm at screening.
  • Subjects with mild to moderate depression or anxiety may be included if their condition is stable.

Exclusion criteria

Exclusion Criteria:

  • Subjects with a history of a suicide attempt or any suicidal behavior in the past two years.
  • Subjects with severe depression or anxiety.
  • Subjects with psychosis, panic disorder, bipolar disorder, post traumatic stress disorder (PTSD), or schizophrenia.
  • Subjects with alcohol or substance abuse or dependence (except nicotine) unless in full remission for at least 12 months.
05

Study design

Phase
Phase 4
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,510 participants (actual)

Study arms

  • Active comparator
    Varenicline Tartrate

    Drug: Varenicline Tartrate

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Varenicline Tartrate oral tablets 2 (0.5mg) tablets twice a day for 24 weeks (first week titration)

  • DrugPlacebo

    Matching placebo 2 oral tablets twice a day for 24 weeks (first week titration)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Carbon Monoxide (CO) Confirmed 10-Week Continuous Abstinence (CA) From Smoking

    Percentage of participants who remained abstinent from Week 15 to Week 24, inclusive, reporting no smoking and no use of nicotine-containing products since the last study visit or contact on the Nicotine Use Inventory (NUI) and confirmed by expired CO \< 10 ppm at any time point (CO measurements conducted at the clinic visits) during Weeks 15 through 24, inclusive. Missing CO was imputed as negative (CO ≤ 10 ppm).

    Time frame: Week 15 - 24

Secondary outcomes

  1. Percentage of Participants With CO Confirmed 4-Week CA From Smoking

    Percentage of participants who remained abstinent from Week 21 to Week 24, inclusive, reporting no smoking and no use of nicotine-containing products since the last study visit or contact on the NUI and confirmed by expired CO \< 10 ppm at any time point (CO measurements conducted at the clinic visits) during Weeks 21 through 24, inclusive. Missing CO was imputed as negative (CO ≤ 10 ppm).

    Time frame: Week 21 - 24

  2. Percentage of Participants With CO Confirmed Long Term CA From Smoking

    Percentage of participants who remained abstinent from Week 21 to Week 52, inclusive, reporting no smoking and no use of nicotine-containing products since the last study visit or contact on the NUI and confirmed by expired CO \< 10 ppm at any time point (CO measurements conducted at the clinic visits) during Weeks 21 through 52, inclusive. Missing CO was imputed as negative (CO ≤ 10 ppm).

    Time frame: Weeks 21 - 52

  3. Percentage of Participants With 7-Day Point Prevalence of Smoking Cessation

    The 7-day point prevalence of abstinence was defined as being abstinent from smoking and using tobacco products during the last 7 days at Week 12, 24, and 52. The participant's smoking status and other nicotine use was evaluated based on the "last 7 days" questions on the NUI and confirmed by CO expiration. Responders were defined as those, who answered "no" to both questions ("Has the subject smoked any cigarettes (even a puff) in the last 7 days?"; and "Has the subject used any nicotine products and/or other tobacco.... in the last 7 days?") and whose expired CO \< 10 ppm. Missing CO was imputed as negative (CO ≤ 10 ppm).

    Time frame: Week 12, 24, and 52

  4. Percentage of Participants With 4-Week Point Prevalence of Smoking Cessation

    The 4-week point prevalence of abstinence was defined as being abstinent from smoking and using tobacco products during the last 4 weeks of the study. The participant's smoking status and other nicotine use was evaluated based on the "last 4 weeks" questions on the NUI and confirmed by CO expiration. Responders were defined as those, who answered "no" to both questions ("Has the subject smoked any cigarettes (even a puff) in the last 4 weeks?"; and "Has the subject used any nicotine products and/or other tobacco.... in the last 4 weeks?") and whose expired CO \< 10 ppm. Missing CO was imputed as negative (CO ≤ 10 ppm).

    Time frame: Week 52

07

Results

Posted Sep 1, 2014
Limitations and caveats
Two cases of fetal exposure during pregnancy occurred but are not included in the SAE section as they did not meet the criteria of serious in the safety database. One of them relates to a non-study participant who was the study participant's partner.

Participant flow

A total of 1747 participants were screened, whereof 1510 were randomized into the study, and of whom 1493 took at least 1 dose of study drug. Overall, 61 centers in 10 countries received study drug: Australia (4), Canada (6), Czech Republic (6), Germany (6), Egypt (3), United Kingdom (7), Japan (6), Mexico (4), Taiwan (7), and USA (12).

Participant flow — Overall Study
MilestoneVareniclinePlacebo
Started751742
Completed559515
Not completed192227
Withdrew: Death10
Withdrew: Lack of efficacy628
Withdrew: Lost to follow-up7681
Withdrew: Withdrawal by subject5459
Withdrew: Reason not specified3943
Withdrew: Protocol violation33
Withdrew: Adverse event (ae) related to study drug129
Withdrew: Ae not related to study drug14

Outcome measures

PrimaryPercentage of Participants With Carbon Monoxide (CO) Confirmed 10-Week Continuous Abstinence (CA) From Smoking

Percentage of participants who remained abstinent from Week 15 to Week 24, inclusive, reporting no smoking and no use of nicotine-containing products since the last study visit or contact on the Nicotine Use Inventory (NUI) and confirmed by expired CO \< 10 ppm at any time point (CO measurements conducted at the clinic visits) during Weeks 15 through 24, inclusive. Missing CO was imputed as negative (CO ≤ 10 ppm).

Time frame:
Week 15 - 24
Reported as:
Number · percentage of participants
Percentage of Participants With Carbon Monoxide (CO) Confirmed 10-Week Continuous Abstinence (CA) From Smoking
percentage of participantsVareniclinePlacebo
Percentage of Participants With Carbon Monoxide (CO) Confirmed 10-Week Continuous Abstinence (CA) From Smoking32.16.9
Statistical analysis
  • Varenicline vs Placebo · Regression, Logistic · p = <0.0001 (Statistical test was 2-sided and a 0.05 level of significance was used. A fixed-sequence procedure was used to adjust for multiplicity. Hierarchy of comparisons: 1) 10-week CA for Weeks 15 - 24, 2) CA for Weeks 21 - 24, 3) CA for Weeks 21 - 52.) · Odds ratio (or): 8.74 · 95% CI 6.09 to 12.53
SecondaryPercentage of Participants With CO Confirmed 4-Week CA From Smoking

Percentage of participants who remained abstinent from Week 21 to Week 24, inclusive, reporting no smoking and no use of nicotine-containing products since the last study visit or contact on the NUI and confirmed by expired CO \< 10 ppm at any time point (CO measurements conducted at the clinic visits) during Weeks 21 through 24, inclusive. Missing CO was imputed as negative (CO ≤ 10 ppm).

Time frame:
Week 21 - 24
Reported as:
Number · percentage of participants
Percentage of Participants With CO Confirmed 4-Week CA From Smoking
percentage of participantsVareniclinePlacebo
Percentage of Participants With CO Confirmed 4-Week CA From Smoking37.812.5
Statistical analysis
  • Varenicline vs Placebo · Regression, Logistic · p = <0.0001 (Statistical test was 2-sided and a 0.05 level of significance was used. A fixed-sequence procedure was used to adjust for multiplicity. Hierarchy of comparisons: 1) 10-week CA for Weeks 15 - 24, 2) CA for Weeks 21 - 24, 3) CA for Weeks 21 - 52.) · Odds ratio (or): 5.66 · 95% CI 4.21 to 7.61
SecondaryPercentage of Participants With CO Confirmed Long Term CA From Smoking

Percentage of participants who remained abstinent from Week 21 to Week 52, inclusive, reporting no smoking and no use of nicotine-containing products since the last study visit or contact on the NUI and confirmed by expired CO \< 10 ppm at any time point (CO measurements conducted at the clinic visits) during Weeks 21 through 52, inclusive. Missing CO was imputed as negative (CO ≤ 10 ppm).

Time frame:
Weeks 21 - 52
Reported as:
Number · percentage of participants
Percentage of Participants With CO Confirmed Long Term CA From Smoking
percentage of participantsVareniclinePlacebo
Percentage of Participants With CO Confirmed Long Term CA From Smoking27.09.9
Statistical analysis
  • Varenicline vs Placebo · Regression, Logistic · p = <0.0001 (Statistical test was 2-sided and a 0.05 level of significance was used. A fixed-sequence procedure was used to adjust for multiplicity. Hierarchy of comparisons: 1) 10-week CA for Weeks 15 - 24, 2) CA for Weeks 21 - 24, 3) CA for Weeks 21 - 52.) · Odds ratio (or): 4.02 · 95% CI 2.94 to 5.50
SecondaryPercentage of Participants With 7-Day Point Prevalence of Smoking Cessation

The 7-day point prevalence of abstinence was defined as being abstinent from smoking and using tobacco products during the last 7 days at Week 12, 24, and 52. The participant's smoking status and other nicotine use was evaluated based on the "last 7 days" questions on the NUI and confirmed by CO expiration. Responders were defined as those, who answered "no" to both questions ("Has the subject smoked any cigarettes (even a puff) in the last 7 days?"; and "Has the subject used any nicotine products and/or other tobacco.... in the last 7 days?") and whose expired CO \< 10 ppm. Missing CO was imputed as negative (CO ≤ 10 ppm).

Time frame:
Week 12, 24, and 52
Reported as:
Number · percentage of participants
Percentage of Participants With 7-Day Point Prevalence of Smoking Cessation
percentage of participantsVareniclinePlacebo
Week 1231.26.7
Week 2443.217.5
Week 5234.118.3
Statistical analysis
  • Varenicline vs Placebo · Regression, Logistic · p = <0.0001 (Statistical test was 2-sided and a 0.05 level of significance was used.) · Odds ratio (or): 8.69 · 95% CI 6.03 to 12.51
  • Varenicline vs Placebo · Regression, Logistic · p = <0.0001 (Statistical test was 2-sided and a 0.05 level of significance was used.) · Odds ratio (or): 4.58 · 95% CI 3.51 to 5.98
  • Varenicline vs Placebo · Regression, Logistic · p = <0.0001 (Statistical test was 2-sided and a 0.05 level of significance was used.) · Odds ratio (or): 2.66 · 95% CI 2.05 to 3.44
SecondaryPercentage of Participants With 4-Week Point Prevalence of Smoking Cessation

The 4-week point prevalence of abstinence was defined as being abstinent from smoking and using tobacco products during the last 4 weeks of the study. The participant's smoking status and other nicotine use was evaluated based on the "last 4 weeks" questions on the NUI and confirmed by CO expiration. Responders were defined as those, who answered "no" to both questions ("Has the subject smoked any cigarettes (even a puff) in the last 4 weeks?"; and "Has the subject used any nicotine products and/or other tobacco.... in the last 4 weeks?") and whose expired CO \< 10 ppm. Missing CO was imputed as negative (CO ≤ 10 ppm).

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With 4-Week Point Prevalence of Smoking Cessation
percentage of participantsVareniclinePlacebo
Percentage of Participants With 4-Week Point Prevalence of Smoking Cessation32.817.3
Statistical analysis
  • Varenicline vs Placebo · Regression, Logistic · p = <0.0001 (Statistical test was 2-sided and a 0.05 level of significance was used.) · Odds ratio (or): 2.67 · 95% CI 2.05 to 3.47

Adverse events

Collected over All AEs (serious and nonserious) were recorded from the date of first dose of study drug (Baseline) up to 30 days after the date of last dose of study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Varenicline—28/751 (3.7%)467/751 (62.2%)
Placebo—16/742 (2.2%)339/742 (45.7%)
Most frequent serious events
Showing 10 of 53
Most frequent serious events
EventVareniclinePlacebo
Myocardial infarctionCardiac disorders0/7512/742
Ovarian cystReproductive system and breast disorders2/7510/742
VertigoEar and labyrinth disorders0/7511/742
IleusGastrointestinal disorders0/7511/742
VomitingGastrointestinal disorders0/7511/742
Chest painGeneral disorders1/7511/742
CellulitisInfections and infestations0/7511/742
Lobar pneumoniaInfections and infestations0/7511/742
PeritonitisInfections and infestations0/7511/742
ContusionInjury, poisoning and procedural complications0/7511/742
Most frequent other events
Most frequent other events
EventVareniclinePlacebo
NauseaGastrointestinal disorders209/75167/742
NasopharyngitisInfections and infestations98/75189/742
Abnormal dreamsPsychiatric disorders86/75143/742
InsomniaPsychiatric disorders80/75151/742
AnxietyPsychiatric disorders52/75165/742
Upper respiratory tract infectionInvestigations63/75163/742
HeadacheNervous system disorders62/75154/742
FatigueGeneral disorders46/75134/742
IrritabilityGeneral disorders39/75130/742
ConstipationGastrointestinal disorders38/75113/742

Baseline characteristics

Age, Continuous
Age, Continuous(Years)VareniclinePlaceboTotal
Mean44.7 ± 11.844.4 ± 12.044.6 ± 11.9
Sex: Female, Male
Sex: Female, Male(Participants)VareniclinePlaceboTotal
Female330321651
Male421421842
08

Study locations

65 sites
  • Pharmacology Research Institute
    Encino, California 91316, United States
  • Pharmacology Research Institute
    Newport Beach, California 92660, United States
  • Clinical Neuroscience Solutions, Inc.
    Jacksonville, Florida 32216, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32806, United States
  • Central Kentucky Research Associates, Inc.
    Lexington, Kentucky 40509, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • The Center for Pharmaceutical Research, P.C.
    Kansas City, Missouri 64114, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198-5910, United States
  • CRI Worldwide, LLC
    Marlton, New Jersey 08053, United States
  • Clinical Research Integrity(CRI) Worldwide, LLC
    Willingboro, New Jersey 08046, United States
  • Central New York Clinical Research
    Manlius, New York 13104, United States
  • FutureSearch Clinical Trials, L.P.
    Austin, Texas 78731, United States
  • Benchmark Research
    Fort Worth, Texas 76135, United States
  • Healthfirst Medical Group
    Fort Worth, Texas 76135, United States
  • Australian Clinical Research Network
    Maroubra, New South Wales 2035, Australia
  • Brisbane South Clinical Research Centre
    Carina Heights, Queensland 4152, Australia
  • Royal Brisbane and Women's Hospital
    Herston, Queensland 4029, Australia
  • Emeritus Research
    Malvern, Victoria 3145, Australia
  • Office of Dr. Ronald Collette
    Burnaby, British Columbia V5G 1T4, Canada
  • James K. Lai, MD., Inc.
    Vancouver, British Columbia V5K 1K3, Canada
  • White Hills Medical Clinic
    St. John's, Newfoundland and Labrador A1A 3R5, Canada
  • Canadian Phase Onward Inc.
    Toronto, Ontario M3H 5S4, Canada
  • Manna Research
    Toronto, Ontario M9W 4L6, Canada
  • Clinique des Maladies Lipidiques de Quebec (CMLQ)
    Quebec, G1V 4M6, Canada
  • SurGal Clinic s.r.o.
    Brno, 602 00, Czech Republic
  • Fakultni nemocnice u sv. Anny v Brne
    Brno, 656 91, Czech Republic
  • Krajska nemocnice Liberec a.s., Plicni oddeleni
    Liberec 1, 460 01, Czech Republic
  • Mestska nemocnice Ostrava, Plicni oddeleni
    Ostrava 1, 728 80, Czech Republic
  • Vseobecna fakultni nemocnice v Praze, III. interni klinika
    Praha 2, 120 00, Czech Republic
  • Vseobecna fakultni nemocnice v Praze
    Praha 2, 120 00, Czech Republic
  • Ustredni vojenska nemocnice Praha
    Praha 6, 169 02, Czech Republic
  • Alexandria University
    Alexandria, Egypt
  • Ain Shams University Hospital
    Cairo, Egypt
  • El Fayoum university hospital
    El Fayoum, Egypt
  • Klinische Forschung Berlin
    Berlin, 10787, Germany
  • Klinische Forschung Berlin-Buch GmbH
    Berlin, 13125, Germany
  • Universitaetsklinikum Goettingen Zentrum Innere Medizin Abteilung Kardiologie und Pneumologie
    Goettingen, 37075, Germany
  • Universitaetsklinikum Goettingen, Zentrum Innere Medizin, Abteilung Kardiologie und Pneumologie
    Goettingen, 37075, Germany
  • Klinische Forschung Hamburg GmbH
    Hamburg, 20253, Germany
  • Medamed- Studienambulanz
    Leipzig, 04109, Germany
  • FOCUS Clinical Drug Development GmbH
    Neuss, 41460, Germany
  • Kubo Clinic
    Yokohama, Kanagawa, Japan
  • Nagatsuta family clinic
    Yokohama, Kanagawa, Japan
  • Sakakibara Clinic, Wakaumekai Medical Corporation
    Yokohama, Kanagawa, Japan
  • Saino Clinic
    Tokorozawa, Saitama, Japan
  • Tajima Clinic
    Edogawa-ku, Tokyo, Japan
  • Hachiouji Junkanki clinic
    Hachiouji, Tokyo, Japan
  • Arke Estudios Clinicos S.A.
    Mexico, D.f. 06700, Mexico
  • Centro Respiratorio de Mexico S.C.
    Mexico, D.f. 14050, Mexico
  • Clinica de Enfermedades Cronicas y de Procedimientos Especiales S.C.
    Morelia, Michoacan 58249, Mexico
  • Centro de Estudios Clinicos y Especialidades Medicas SC
    Monterrey, Nuevo Leon 64620, Mexico
  • Chang Gung Medical Foundation-Linkou Branch
    Kweishan Town, Taoyuan County 333, Taiwan
  • Kaohsiung Veterans General Hosptial
    Kaohsiung, 813, Taiwan
  • China Medical University Hospital
    Taichung, 404, Taiwan
  • Taichung Veterans General Hospital
    Taichung, 40705, Taiwan
  • National Cheng Kung University Hospital
    Tainan, 704, Taiwan
  • National Taiwan University Hospital, Department of Family Medicine
    Taipei, 100, Taiwan
  • Taipei Veterans General Hospital
    Taipei, 112, Taiwan
  • Enchord Limited
    Fowey, Cornwall PL23 1DT, United Kingdom
  • The Alverton Practice
    Penzance, Cornwall TR18 4JH, United Kingdom
  • Knowle House Surgery
    Plymouth, Devon PL5 3JB, United Kingdom
  • Castlemilk Health Centre
    Castlemilk, Glasgow G45 9EW, United Kingdom
  • Prince Philip Hospital
    Dafen, Llanelli SA14 8QF, United Kingdom
  • Hathaway Medical Centre
    Chippenham, Wilts SN14 8GT, United Kingdom
  • The Jenner Practice
    London, SE23 1HU, United Kingdom
09

References and documents

Publications

  • Hartmann-Boyce J, Theodoulou A, Farley A, Hajek P, Lycett D, Jones LL, Kudlek L, Heath L, Hajizadeh A, Schenkels M, Aveyard P. Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev. 2021 Oct 6;10(10):CD006219. doi: 10.1002/14651858.CD006219.pub4. PubMed 34611902 ↗
  • Nakamura M, Abe M, Ohkura M, Treadow J, Yu CR, Park PW. Efficacy of Varenicline for Cigarette Reduction Before Quitting in Japanese Smokers: A Subpopulation Analysis of the Reduce to Quit Trial. Clin Ther. 2017 Apr;39(4):863-872. doi: 10.1016/j.clinthera.2017.03.007. Epub 2017 Mar 30. PubMed 28365035 ↗
  • Ebbert JO, Hughes JR, West RJ, Rennard SI, Russ C, McRae TD, Treadow J, Yu CR, Dutro MP, Park PW. Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial. JAMA. 2015 Feb 17;313(7):687-94. doi: 10.1001/jama.2015.280. PubMed 25688780 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2014, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2011
First posted
Jun 9, 2011
Start
Jul 2011
Primary completionActual
Jul 2013
CompletionActual
Jul 2013
Results first posted
Sep 1, 2014
Last update
Sep 1, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01370356
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 9, 2011
Start date
Jul 2011
Primary completion
Jul 2013
Completion
Jul 2013
Results posted
Sep 1, 2014
Last update
Sep 1, 2014

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Varenicline

Start the discussion